COMMUNIQUÉS West-GlobeNewswire

Curetis' Subsidiary Ares Genetics Initiates Development of AI-Powered Infectious Disease Test
04/09/2018
Curetis' Subsidiary Ares Genetics Initiates Development of AI-Powered Infectious Disease Test ARESupa test aims at broad detection of microbial infections employing next-generation sequencing and artificial intelligence [...]
Santhera Announces Financial Results for the First Half-Year 2018 and Updates on Operational Progress and Growth Strategy
04/09/2018
A conference call will be held today at 13:00 CEST, 12:00 BST, 07:00 EDT. Details are at the end of this statement. Pratteln, Switzerland, September 4, 2018 - Santhera Pharmaceuticals (SIX: SANN) reports first half-year [...]
Probiodrug Appoints Dr. Michael Schaeffer as Executive Vice President of Business and Strategy
04/09/2018
Probiodrug Appoints Dr. Michael Schaeffer as Executive Vice President of Business and Strategy HALLE (SAALE), Germany, 04 September, 2018: Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical [...]
Inovio and Korean Partner Dose 1st Subject In Trial to Develop World’s First Vaccine to Prevent Hepatitis C Infection
04/09/2018
While new therapies have made hepatitis C a curable infection, no preventive vaccine has ever been approved PLYMOUTH MEETING, Pa., and SEOUL, Korea, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. ( [...]
Addex’s Selective mGlu2 PAM ADX71149 Shows Promise in Treating Severe Panic Disorders and PTSD
04/09/2018
Preclinical and Adhoc Clinical Data Published in Molecular Psychiatry Geneva, Switzerland, 4 September 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and [...]
Ossur Hf : Transactions in relation to share buyback program
03/09/2018
Announcement no. 53/2018 3 September 2018 Transactions in relation to share buyback program On 5 March 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 16/2018. The purpose of the share [...]
Nicox: Number of voting rights as of August 31, 2018
03/09/2018
Nicox SA Société anonyme with a registered capital of € 29,588,510 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On September 3, 2018, MONTHLY PUBLICATION OF THE [...]
Nicox : Nombre total de droits au 31 août 2018
03/09/2018
Nicox SA Société anonyme au capital de 29 588 510 euros Siège social : DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 3 septembre 2018, PUBLICATION MENSUELLE DU NOMBRE D' [...]
Nicox confirme son éligibilté au PEA-PME
03/09/2018
Communiqué de presse Nicox confirme son éligibilité au PEA-PME ................................................. 3 septembre 2018 Sophia Antipolis, France / Research Triangle Park, NC, Etats-Unis Nicox SA (Euronext [...]
ThromboGenics becomes "Oxurion"
03/09/2018
Press release Shareholders approve new name which better reflects the Company's ambition to deliver best in class therapies for back of the eye disorders Leuven, Belgium, 3 September 2018 - ThromboGenics NV (Euronext [...]
Oncology Venture AS buyes 5% points Dovitinib ownership from Sass & Larsen and prolong buy back option on 30%
03/09/2018
Press release September 3, 2018 Oncology Venture AS buys 5% points Dovitinib ownership from Sass & Larsen and prolong buy-back option on 30% Hoersholm, Denmark, September 3, 2018 Oncology Venture A/S ("Oncology [...]
NeoChord Announces Successful Completion of First Beating Heart Repair Procedures in China
03/09/2018
ST. LOUIS PARK, Minn., Sept. 03, 2018 (GLOBE NEWSWIRE) -- NeoChord, Inc. , a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve [...]
Transactions under Novozymes’ stock buyback program
03/09/2018
Please read the full announcement in the attached PDF Attachment 2018_52_Stock_Buybackprogram_EN
Total voting rights
03/09/2018
Summit Therapeutics plc (‘the Company’) Total voting rights Oxford, UK, and Cambridge, MA, US 3 September 2018 – Summit Therapeutics plc (AIM:SUMM, NASDAQ:SMMT), announces that in accordance with the FCA's Disclosure [...]
Progress Towards Clinical Development of IMP761 – a LAG-3 Agonist Antibody
03/09/2018
SYDNEY, Australia, Sept. 03, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”, the “Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune [...]
Novo Nordisk A/S - Share repurchase programme
03/09/2018
Bagsværd, Denmark, 3 September 2018 - On 10 August 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
GUERBET : Information sur les opération effectuées dans le cadre du programme de rachat d'actions
03/09/2018
Villepinte (France), le 03 septembre 2018 Le présent document a pour finalité de présenter les opérations réalisées dans le cadre du programme de rachat d'actions autorisé par l'Assemblée Générale Mixte du 25 mai 2018 [...]
Acarix Clinical Advisory Board meeting held in parallel to ESC-conference in Munich, Germany, confirms validity of its comprehensive clinical study program.
03/09/2018
Press release Malmö, Sept 3, 2018 Acarix Clinical Advisory Board meeting held in parallel to ESC-conference in Munich, Germany, confirms validity of its comprehensive clinical study program. Acarix AB (publ) ("Acarix [...]
Total voting rights
03/09/2018
Summit Therapeutics plc (‘the Company’) Total voting rights Oxford, UK, and Cambridge, MA, US 3 September 2018 – Summit Therapeutics plc (AIM:SUMM, NASDAQ:SMMT), announces that in accordance with the FCA's Disclosure [...]

Pages